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1. Introduction 
To expand without limitation cancerous cells have to acquire the ability to proliferate 
without external or internal restrictions. Whereas almost all normal cells within a body will 
not proliferate without external mitogenic stimuli cancer cells gain defects in growth factor 
signaling control that mimic external stimulation and thus allow them to divide. However, 
this unrestricted proliferation also activates an internal barrier to transformation, i.e. it 
induces the expression of so called cell cycle brakes that stop unrestricted growth at the very 
basal level of the cell cycle. These cell cycle inhibitors prevent increased cycling by 
controlling the activity of cyclin/CDK holoenzyms which are the central promoters of cell 
cycle progression. These cell cycle inhibitors or “brakes” are divided into two families, the 
INK4 inhibitors and the Cip/Kip inhibitor family. In this chapter we will mainly focus on 
the INK4 inhibitor protein p16INK4A which is encoded by the INK4A gene locus. 
Inactivation of the INK4A gene locus occurs frequently in primary tumor cells of T-cell acute 
lymphoblastic leukemia (T-ALL), suggesting a critical role of this locus in disease 
development. Its deletion predicts relapse in childhood acute lymphoblastic leukemia 
(ALL). Interestingly, this gene locus also represents a main barrier to the generation of 
induced progenitor stem (iPS) cells and evidence has been provided that downregulation of 
p16INK4A is associated with enhanced self-renewal and proliferative capacity of 
hematopoietic stem cells. This suggests that the inactivation of this tumor suppressor in 
immature pre-cancerous cells might allow them to overcome replicative senescence. 
Importantly, p16INK4A exerts its effects not only on cell cycle control but changes cell death 
sensitivity of T-ALL cells by affecting glucocorticoid sensitivity, death receptor-mediated- 
and intrinsic programmed cell death pathways that are controlled at the level of BCL2 
proteins. These effects of p16INK4A on the cell death machinery in ALL cells support the 
notion that loss of the INK4A gene locus has a two-sided effect during the development of 
ALL, on one hand it allows unrestricted proliferation of ALL progenitor cells and on the 
other hand this deletion rescues leukemic cells from cell death. Thus, the effects of 
p16INK4A in hematopoietic cells and during leukemia development seem to be much more 






2. Stop or go: A general overview on cell cycle entry 
Proliferating eukaryotic cells pass through a complex cell division cycle that is divided into 
four phases: the gap-phase before DNA replication (G1-phase), the phase of DNA synthesis 
(S-phase), the gap after DNA synthesis (G2-phase) and mitosis (M-phase). Whereas the 
length of DNA-synthesis, G2 and M-phase are relatively constant within different cell types, 
the greatest variation is observed in the duration of G1. Highly proliferative cells pass 
through this phase within a few hours; differentiated cells, on the other hand, may stay in 
this cell cycle stage for months, years, or even life time. This situation of final differentiation 
is called G0. The G0/G1 cell cycle state is usually considered as the time window, in which a 
cell decides whether to proliferate or to arrest.  
Progression through the cell cycle is governed by a family of serine-threonine kinases called 
cyclin-dependent kinases (CDKs) that associate with different cyclins in distinct phases of 
the cell cycle (Murray and Hunt 1993; Sherr and Roberts 2004). Whereas the cellular 
concentration of CDK proteins does not vary significantly during cell cycle, the levels of 
cyclins undergo dramatic changes during the different phases. They reach characteristic 
peak levels in specific cell cycle phases and are degraded in other phases.  
When quiescent cells re-enter the cell cycle, D-type and E-type cyclins are synthesized 
sequentially during the G1 interval; both types are rate-limiting for S-phase entry (Quelle et 
al, 1993). Cyclin Ds assemble with CDK4 (Matsushime et al, 1992) and CDK6 (Meyerson and 
Harlow 1994) and these complexes are activated by phosphorylation via the so called cyclin 
activating kinase (Murray and Hunt 1993). Critical substrates of G1 cyclin/CDK complexes 
are the retinoblastoma gene product pRB and its family members p107 and p130, which are 
transcriptional repressors that are bound to transcription factors essential for S-phase entry 
(Cobrinik 2005; Grana et al, 1998). Upon phosphorylation on distinct sites by both, cyclin 
D/CDK4/6 and cyclin E/CDK2 complexes pRB and its family members lose their function 
as transcriptional repressors thereby activating the transcription of genes essential for S-
phase progression. The activity of CDK4, CDK6 and CDK2 is regulated by mitogenic 
hormones and by binding of CDK inhibitors (CDKI) of the INK4A family, like p16INK4A, 
and of the Cip/Kip family, i.e. p21Cip1, p27Kip1 and p57Kip2 (Sherr and Roberts 1999; 
Ekholm and Reed 2000) (see Figure 1). 
3. The strange case of INK4A: One gene locus that codes for two unrelated 
tumor suppressors 
The INK4A gene locus on chromosome 9p21 codes for the two functionally fully unrelated 
tumor suppressor genes p16INK4A and ARF (known as p14ARF in human and p19ARF in 
mouse). As outlined above, p16INK4A/CDKN2A was originally identified as a cyclin-
dependent kinase inhibitor that, like its family members p15INK4B, p18INK4C and 
p19INK4D, binds to the kinase subunits CDK4 and CDK6 of D-type cyclins. Cyclin D1, D2 
and D3 govern the decision of cell cycle entry from quiescent G0 state. In contrast to other 
cyclins the activity of cyclin Ds/CDK4 and CDK6 holoenzymes is controlled by various 
survival signaling pathways e.g. by Ras/Raf signaling, by the PI3K/PKB pathway  or by the 
Wnt signaling pathway which are frequently perturbed in cancer cells thereby leading to 
aberrant cell cycle entry and cell proliferation. p16INK4A and other inhibitors of the INK4-
family (INK4 means “inhibitor of kinase 4”) thereby represent a main barrier to increased 
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lack functional pRB, either by mutation or due to viral proteins that target and inactivate 
pRB, usually show high levels of p16INK4A (Aagaard et al, 1995). In such cells CDK4 and 
CDK6 do not interact with D-type cyclins but form stable, long half-life, binary complexes 
with p16INK4A (Parry et al, 1995) demonstrating that the cell cycle inhibitory effect of 
p16INK4A depends on the functionality of the tumor suppressor pRB.  
 
 
Fig. 1. Dynamic accumulation and assembly of cyclin/CDK complexes in different phases of 
the cell cycle. Schematic presentation of the cell cycle with emphasis on the G1/S checkpoint 
regulation by CDK inhibitors, detailed explanation in the text. 
However nature has found an elegant way of redundancy to compensate for the loss of 
p16INK4A function in pRB-deficient tumors by an alternative protein. Adjacent to the 
INK4A gene locus on chromosome 9p21 an additional promoter region exists that produces 
a transcript which includes exon 2 and exon 3 of p16INK4A but has an alternate exon 1 
(exon1┚) (Figure 2). Since the exon 2 is translated in an alternative reading frame (ARF) the 
resulting protein is completely unrelated to the gene product of INK4A although it shares 
parts of the mRNA sequence (Quelle et al, 1995). p16INK4A and ARF have no similarities in 
amino acid composition and are two completely different proteins with distinct functions – 
but both act as efficient tumor suppressors (Figure 2). This is demonstrated by the fact that 
mice that are deficient for either ARF or p16INK4A have increased susceptibility to 
spontaneous or carcinogen-induced cancers (Sharpless et al, 2001; Kamijo et al, 1997). 
p16INK4A-deficient mice show a much less spontaneous tumor rate than ARF null mice. 
p16INK4A ablation leads to spontaneous sarcomas and lymphomas within 17 months 
(Sharpless et al, 2001), whereas the onset of spontaneous sarcomas, carcinomas and 
lymphomas in ARF-null mice is already observed at the age of 9 months (Kamijo et al, 1997). 
However, it is difficult to compare results from ARF null mice with the situation in human 
cells since human (p14ARF) and mouse p19ARF share only about 50% sequence homology. 
In addition there are apparent regulatory and functional differences between human and 
mouse ARF. Whereas in senescent mouse fibroblasts p19ARF accumulates and is critical for 
senescence-induced growth arrest, the human p14ARF seems not involved and is 






mainly controlled by the unrelated twin p16INK4A and the relevance of p14ARF seems also 
limited for other processes such as prevention of “stemness” in normal human fibroblasts by 
the expression of specific transcription factors (see below). 
Human or murine ARF proteins do not contain any recognizable structural motifs and 
probably need to interact with other proteins to form functional complexes. The first 
discovered and best-defined function of ARF is the induction of p53 via inhibition of the 
p53-degrading E3-ubiquitine ligase MDM2 (mouse) or HDM2 (human) (Sherr 2006). In 
situations of increased cell cycle progression, e.g. when oncogenic signaling stimulates cell 
cycle entry or loss of pRB function, ARF is transcriptionally induced via E2F1/DP1 and 
binds to and inhibits MDM2 or HDM2, respectively. This leads to accumulation of p53 and 
induction of p53-induced response genes, such as p21Cip1 that interferes with cell cycle 
progression, or the proapoptotic BCL-2 proteins BBC3/PUMA and PMAIP1/Noxa that 
induce programmed cell death (Villunger et al, 2003). More recently other functions of ARF 
have been discovered: in response to oncogenic stress ARF enters the nucleolus and retards 
rRNA transcription thereby inhibiting ribosome biosynthesis (Itahana et al, 2003) and ARF 
influences the ATM/ATR kinases during the DNA-damage response in a p53-independent 
manner (Rocha et al, 2005). Moreover, it was shown that independent of p53 ARF 
antagonizes the activity of two other critical factors for cell cycle entry, namely E2F and Myc 
(Sherr 2006). The detailed investigation of how p16INK4A and ARF control cell survival and 
proliferation in distinct cell types will remain a highly interesting field of research in the 
next years, in particular the physiologic role of these two unrelated twins in non-
transformed somatic cells. 
4. The role of the INK4A locus for the generation of induced pluripotent stem 
cells (iPS) 
Tissue repair and permanent replacement of damaged or aged cells are essential for the life 
of complex organisms and usually depend on a distinct, unspecialized stem cell population 
with almost unlimited proliferative capacity. With age, the capacity of these stem cells to 
proliferate and generate progenitors declines, which may also contribute for many age-
related symptoms. The reprogramming of normal, differentiated cells by the three 
transcription factors Oct4, Klf4, and Sox2 has opened a completely new field of research and 
raised the hope to regenerate almost all cell types and tissues within the human body by 
generating stem cells from somatic cells of a patient. However the process that is initiated by 
these three transcription factors works at low efficiency and remains poorly understood. In 
embryonal stem cells and in induced progenitor stem (iPS) cells the INK4A gene locus is 
completely silenced and neither p16INK4A nor ARF are expressed. The lack of INK4A 
proteins seems to be a hallmark of different kinds of stem cells. Interestingly, this epigenetic 
silencing is not due to enhanced DNA-methylation of the INK4A promoters but results from 
so called “bivalent chromatin” which is present at the INK4A gene locus (Ohm et al, 2007). 
“Bivalent” means that repressive methylation marks (H3K27me3) and activating 
methylation marks (H3K4me3) are present on the same histone molecule, leading to a 
chromatin state that silences gene expression but can be reversed during differentiation of a 
cell. Such domains are characteristics of embryonal stem cells and are frequently associated 
with binding sites for Oct4 and Sox2. Although such binding sites are absent in the INK4A 
gene locus the presence of these bivalent domains suggests that the INK4A gene locus 
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silencing, retains the ability to be re-activated during differentiation processes (Li et al, 
2009). It is well established that the rate of induced pluripotent stem cells generated from 
somatic cells significantly drops with the age of the organism they are obtained from. In 
humans also the cellular levels of p16INK4A increase with age. Back to back several 
different groups showed in 2009 that the INK4A gene locus critically impairs successful 
reprogramming to pluripotent stem cells and that it represents a main barrier to iPS cell 
programming (Utikal et al, 2009; Marion et al, 2009; Banito et al, 2009; Li et al, 2009). Also in 
these papers the differences of p16INK4A and ARF between murine and human cells 
become evident: In mouse cells, the ARF-p53 pathway has more impact on preventing the 
generation of pluripotent stem cells from somatic cells, whereas p16INK4A seems to play a 
minor role in the mouse. In human fibroblasts, knockdown of ARF does not affect at all the 
generation of iPS cells whereas knockdown of p16INK4A significantly improved 
reprogramming efficiency. This suggests that depending on the species, either p16INK4A or 
ARF represent a barrier to “back-differentiation” of normal somatic cells and prevent the 
induction of “stemness” in cells that have differentiated into a certain lineage. This makes 
this gene locus so important for the medical application of induced progenitor cells to e.g. 
replace damaged tissue of a patient, but also underlines that p16INK4A and/or ARF may be 
critical for maintaining tissue architecture and function in complex organisms by preventing 
uncontrolled expansion or “development” of somatic cells with stem cell-like abilities.  
5. Regulation of INK4A in hematopoietic stem cells and their progenitors 
As discussed before the INK4A gene locus represents a main barrier to the generation of iPS 
cells. In hematopoietic stem cells and many other stem cell types e.g. neuronal stem cells 
(Molofsky et al, 2006), the INK4A gene locus is not active. In particular the downregulation 
and silencing of p16INK4A seems to be essential for the enhanced self-renewal and 
proliferative capacity of human hematopoietic stem cells (Janzen et al, 2006). At the 
transcriptional level the INK4A expression is modulated by three main regulators, beta 
lymphoma Mo-MLV insertion region (BMI1), ETS1 and inhibitor of DNA binding 1 (Id1) 
whereas age-related induction of p16INK4A and ARF in human cells is mainly related to the 
balance between ETS1 and Id1 proteins (Ohtani et al, 2001). The reversible silencing of this 
gene locus in hematopoietic stem cells can be ascribed to the activity of the BMI1 protein. 
BMI1 belongs to the polycomb group genes, which are transcriptional repressors that 
control gene expression patterns during differentiation and development (Simon and 
Kingston 2009). The polycomb group genes fall into two subgroups that are either part of 
polycomb repression complex 1 (PRC1) or polycomb-repression complex 2 (PRC2). PRC2 is 
the so called “initiation complex” that functions as a histone-methyltransferase which 
specifically methylates histone H3 on lysine 27 causing gene silencing. As outlined above 
methylation of histone H3 on lysine 27 (H3K27me3) and on lysine 4 (H3K4me3) are 
hallmarks of “bivalent” chromatin that is silenced but retains the ability to be reactivated 
upon cell differentiation processes. BMI1 is part of PRC1 which is the so called 
“maintenance complex” that in a second step recognizes trimethylated H3K27. BMI1 
directly associates with the INK4A locus and it was demonstrated that repression of the 
INK4A gene locus depends on the continuous presence of the PRC2 complex (Bracken et al, 
2007). Several lines of evidence suggest that BMI1 is critical for maintaining “stemness” at 
least in human hematopoietic stem cells (Figure 2). In cord blood hematopoietic cells BMI1 






decreases when these cells maturate into more differentiated progenitor cells. 
Overexpression of BMI1 enhances the self-renewal of hematopoietic stem cells, increases the 
engraftment potential and results in stem cell maintenance. Knockdown of BMI1 in cord 
blood CD34+ and in acute myeloid leukemia (AML) CD34+ cells reduces progenitor-
forming capacity, stem cell marker expression and long-term culture-initiating cell 
frequencies significantly suggesting that loss of BMI impairs the maintenance of stem cells 
and progenitor cells. In parallel, because of the gene-silencing effect of the BMI1 containing 
PRC1 complex on the INK4A gene locus, loss of BMI1 in C34+ cord blood and AML cells 
causes the induction of p14ARF and p16INK4A, significantly increased apoptosis and the 
production of cellular reactive oxygen species (Rizo et al, 2009). Lack of BMI1 in 
hematopoietic cells from BMI1 knockout mice also resulted in an increased expression of 
p16INK4A and p19ARF. The fact that the deletion of INK4A/ARF in the BMI1-/- 
background partly restored the self-renewal capacity of hematopoietic stem cells 
demonstrates the importance of silencing of the INK4A gene locus by BMI1 for the 
maintenance of hematopoietic stem cells (Oguro et al, 2006).  
 
 
Fig. 2. The INK4A gene locus generates the two unrelated tumor suppressor proteins 
p16INK4A and ARF by alternative promoter usage and splicing, which are subjected to a 
complex regulation in hematopoietic stem cells and progenitor cells. Stress and senescence 
activate p16INK4A via Ets1/2 transcription factors and accelerated cell cycle entry triggers 
ARF expression. Id1 heterodimerizes and blocks Ets1/2 in young unstressed cells or stem 
cells. In stem cells BMI1 as part of the polycomb complex PRC2 causes epigenetic gene 
silencing of the entire locus by bivalent histone methylation (see text). 
6. Is p16INK4A critical for the development of hematologic malignancies? 
The almost unlimited replicative capacity of stem cells and efficient generation of 
progenitors may be a double edged sword for a multicellular organism. On one hand this 
proliferative capacity allows efficient repair, regeneration and plasticity of tissues, on the 
other hand it increases the risk of acquiring genetic defects in this stem cell population that 
may result in hyperproliferative diseases, among them malignant transformation and 
cancer. Considering the fact that the INK4A gene locus codes for two tumor suppressors 
with completely different functions which either critically control the pRB or the p53 gene 
network, it becomes clear that genetic abnormalities of this gene locus may have a dramatic 
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give rise to leukemia. Due to the unusual structure of this gene locus, mutations often affect 
both, p16INK4A and p14ARF gene products, thereby deleting the gatekeepers of two 
essential check points. This may explain why mutations of the INK4A gene locus are 
observed in almost all human cancers. However, the effects of the INK4A gene products are 
also cell lineage specific, which might explain why some malignancies, for example T-ALL, 
show very high frequencies of homozygous deletion of the INK4A gene locus. Deletions 
frequently affect exon 2, thereby destroying both, p16INK4A and p14ARF, but there are also 
patients with alterations in either exon 1┙ or exon 1┚ which only affect one of the tumor 
suppressors (Cayuela et al, 1996; Cayuela et al, 1997; Hebert et al, 1994; Quelle et al, 1995). In 
addition methylation of the p16INK4A promoter was reported in T-ALL patients, leading to 
permanent silencing of the INK4A gene (Gardie et al, 1998; Drexler 1998). From a prognostic 
point of view inactivation of the INK4A locus seems also highly important for human 
lymphoblastic leukemia. Loss of INK4A predicts relaps in children with acute lymphoblastic 
leukemia suggesting a critical role of this locus in disease development and also 
highlighting the need for additional therapies to treat this subgroup of T-ALL patients (Kees 
et al, 1997); (Okuda et al, 1995). Several attempts have been undertaken to better 
understand, why inactivation of the INK4A gene locus is critical in particular for the 
development of hematopoietic malignancies. One oncogene that is thought to initiate T-cell 
leukemia is the TAL1/SCL oncogene. TAL1/SCL expressing T-ALL patients have a high 
incidence (up to 90%) of deletion of exon 2 in the INK4A gene locus. Although TAL1/SCL 
overexpression induces leukemia in transgenic mice, leukemia by this oncogene is 
characterized by a long latency suggesting that additional genetic events are required 
(Condorelli et al, 1996). To elucidate the contribution of the INK4A gene locus to 
leukemogenesis Shank-Calvo and colleagues (Shank-Calvo et al, 2006) mated TAL1 
transgenic mice with single knockout mice for either p16INK4A or p19ARF. Of note, each of 
these mice developed T-cell leukemia rapidly, indicating that loss of either p16INK4A or 
p19ARF accelerates TAL1-induced leukemia in mice.  
The fact that the INK4A genes are inactivated at high incidence in hematopoietic 
malignancies might be ascribed to the specific roles of these two proteins in slowing down 
the proliferation of hematopoietic progenitor cells, as discussed above. INK4A-/- mice 
possess increased thymus size and cellularity suggesting involvement of p16INK4A in the 
control of thymocyte proliferation. These animals exhibit increased numbers of CD4 and 
CD8 T lymphocytes in thymus and spleen (Bianchi et al, 2006) which also reflects increased 
proliferative potential. By using somatic, tissue specific ablation of p16INK4A in the T- or 
the B-lymphoid progenitor cells it was recently demonstrated that in the T-cell lineage loss 
of p16INK4A attenuated age-dependent thymic involution or increased production of naive 
T-cells. In the B-cell lineage p16INK4A inactivation significantly accelerated lymphoid 
tumorigenesis. Interestingly, the animals mainly suffered from tumors that manifested in 
the central nervous system but still expressed CD45 leukocyte-common antigen. These 
tumor cells were negative for a neuromeningeal marker, proving that they are not brain 
tumors and expressed B-lymphocyte markers demonstrating their B-cell origin (Liu et al, 
2011). In this paper the authors argued therefore that in the T-cell linage p16INK4A merely 
regulates cell senescence in the mouse, whereas in the B-cell lineage loss of p16INK4A 
contributes to lymphoid cancer. These results are contradictory to the high prevalence of 
p16INK4A loss in human T-cell leukemia progenitor cells and may be ascribed to the 
already above discussed differences of the role of p16INK4A and ARF between mice and 






that may be triggered by the two tumor suppressors of the INK4A gene locus. In the next 
chapter we will discuss how p16INK4A affects programmed cell death.  
7. p16INK4A regulates programmed cell death and death sensitivity in 
leukemia cells 
When a cell is hit by a genotoxic insult it will either try to repair the genetic damage or, if 
not possible, undergo programmed cell death. Otherwise the mutation will be inherited to 
the daughter cells, which may give rise to precancerous cells that slowly proceed into 
malignancy. Slowing down cell cycle progression upon genotoxic stress may therefore help 
cells to get time for efficient damage repair and thereby prevent programmed cell death. On 
the other hand cell cycle arrest in the presence of oncogenic signaling may constitute a death 
signal per se since apoptosis may be the only way for a precancerous cell to respond to this 
“conflicting signaling” situation. INK4A gene products are not expressed in hematopoietic 
stem cells and therefore may not play an essential role for the quiescence state that every 
stem cell has to enter after division to preserve its replicatory potential. Instead, INK4A 
proteins accumulate in the progenitor cell population and seem to limit their proliferation.  
As a consequence of p16INK4A deficiency rapid movement through the cell cycle may 
sensitize leukemia cells to genotoxic stress, which has been shown in different types of 
cancer cells. In p16INK4A-deficient MEFs and U2OS osteosarkoma cells the lack of 
p16INK4A sensitizes these cells to cell death induction by UV irradiation, whereas 
p16INK4A-proficient cells are largely resistant. The authors also observed that UV-induced 
apoptosis in p16INK4A-deficient cells coincided with decreased levels of pro-survival BCL2 
and increased levels of pro-apoptotic BAX proteins (Al Mohanna et al, 2004). Moreover, in 
p16INK4A-deficient mice increased numbers of CD4 and CD8 T-cells are found in thymus 
and spleen and these increased cell numbers correlated with reduced T-cell apoptosis in the 
thymus rather than increased proliferation rates (Bianchi et al, 2006). The increased rates of 
DNA-synthesis in p16INK4A-deficient cells may expose an “archilles heel” to DNA-
damage-induced cell death, but there are also data that highlight that p16INK4A 
reconstitution sensitizes T-ALL cells to certain forms of apoptosis. This suggests that 
p16INK4A may exert also additional effects beyond cell cycle inhibition, such as the 
regulation of proteins critical for cell death initiation and cell death decision in mammalian 
cells. We demonstrated already ten years ago that tetracycline-regulated p16INK4A 
reconstitution in p16INK4A-deficient CCRF-CEM cells, a human T-ALL cell line, sensitizes 
these leukemia cells to physiologic levels of cortisol, a glucocorticoid that also plays a 
significant role during T-cell selection and T-cell maturation in the thymus. In this early 
study we were able to show that p16INK4A significantly induces the expression of 
endogenous glucocorticoid receptor thereby markedly lowering the threshold for 
glucocorticoid-induced apoptosis (Ausserlechner et al, 2001). In this paper we discussed that 
loss of p16INK4A in precancerous hematopoietic cells may render them resistant to 
glucocorticoid-induced cell death by physiologic levels of cortisol. Since the strikingly 
increased sensitivity was difficult to explain by increases in receptor levels alone we sought 
for additional mechanisms further downstream of the glucocorticoid receptor that may 
contribute to p16INK4A-regulated death sensitivity. Indeed, also in T-ALL cells activation of 
p16INK4A affects the balance of death inducers and death protectors at the level of 
mitochondria, but also activates death ligands. For studying p16INK4A effects in different 
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based on different tetracycline-activated transactivators and repressors (Ausserlechner et al, 
2006). In Molt4 T-ALL cells, for example, p16INK4A causes increased sensitivity to UV-
irradiation, which is associated with induction of the pro-apoptotic BH3-only protein 
BBC3/Puma (Obexer et al, 2009a). 
In principle programmed cell death can be initiated by a number of different signals 
originating either from outside of the cell (extrinsic pathway) or from intrinsic signals 
(Strasser 2005). Soluble or cell bound death ligands such as FASLG/FAS ligand or TRAIL 
bind to their cognate receptors, thereby inducing the formation of the so called death-
inducing signaling complex (DISC) which contains the adaptor molecule FADD and 
procaspase-8. The autocatalytic cleavage and activation of procaspase-8 triggers the 
downstream caspase cascade. Mitochondria are central decision makers of apoptosis that 
integrate death signals originating from DNA-damage, growth factor withdrawal, 
glucocorticoid-treatment and anoikis. These stimuli trigger cell death either by directly 
regulating cell survival/cell death genes, or by deregulating cellular networks, which leads 
to apoptosis. Pro- and anti-apoptotic BCL2 proteins, referred to as the “BCL2-rheostat”, are 
involved in this cell death decision either as direct targets or as sensors for cellular stress. 
BCL2-proteins can be divided into three groups. The prosurvival multi-domain BCL2-
proteins BCL2, BCL2L2/Bcl-w, BCL2L1/Bcl-xL, BCL2A1/A1 and MCL1 share four BCL2-
homology (BH) domains, whereas multi-domain proapoptotic proteins BAX and BAK1/Bak 
are characterized by three BH-domains (Strasser 2005).  The third group is the family of 
BH3-only proteins which contain only the BH3-domain and heterodimerize with 
prosurvival BCL2-proteins. The two models that have been proposed for apoptosis 
  
 
Fig. 3. Expression of p16INK4A induces growth arrest in the G1 phase of the cell cycle and 
shifts the balance of pro- and anti-apoptotic BCL2 proteins towards the edge of cell death 
(detailed explanations in the text). 
induction by BH3-only proteins suggest that either strong BH3-only proteins such as 
BCL2L11/Bim, truncated Bid or BBC3/Puma directly activate BAX or BAK1 (“direct 
activator/de-repressor model”) (Kim et al, 2006) or that these BH3-only proteins neutralize 






al, 2006; Willis et al, 2007). Upon cell death decision BAX or BAK1 oligomerize in the 
mitochondrial outer membrane which causes cytochrome c release from mitochondria and 
activation of the further downstream apoptosome complex.  
Interestingly, the apoptosis-regulatory effect of conditional reconstitution of p16INK4A in T-
ALL leukemia cells depends on the therapeutic agent that is applied to the cells: p16INK4A 
markedly protects against programmed cell death induced by doxorubicin, etoposide and 
vinblastine (Figure 4), but in parallel sensitizes these cells to FAS- and GC-induced 
apoptosis (Figure 4 and (Obexer et al, 2009a)). Since p16INK4A induces an almost complete 
cell cycle arrest in these cells and uncouples growth from cell cycle arrest (Ausserlechner et 
al, 2005) we believe that this protective effect is merely a consequence of accumulation of 
cells in the G1 phase of the cell cycle. DNA-damaging agents such as doxorubicin or 
etoposide and tubulin-destabilzing compounds such as vinblastine exert their effects mainly 
on proliferating cells in S-phase or mitosis, respectively. Slowly proliferating cells or cells 
that are arrested in the G1-phase of the cell cycle may be therefore more resistant (Bacher et 
al, 2006). However, conditional p16INK4A also protects T-ALL cells against bortezomib-
induced cell death (Figure 4). Although, the proteasome-inhibitor bortezomib/VelcadeTM 
may perturb the correct degradation of cell cycle regulators such as cyclins, it has been 
shown that bortezomib is highly effective on slowly proliferating cancer cells such as 
chronic myeloid leukemia. This suggests that p16INK4A has a direct or indirect affect on cell 
death regulators at the level of death receptors and/or BCL2-proteins. When analyzing the 
expression of death receptors and their ligands it became evident that p16INK4A induces 
FAS-ligand mRNA expression in these cells, but does not change the FAS-receptor 
expression. Since CCRF-CEM cells are FAS-sensitive, this might cause an autocrine death 
signal that lowers death resistance in general since also the FAS downstream effectors 
Caspase-8 and Bid showed accelerated cleavage in p16INK4A expressing cells upon FAS-
induced apoptosis. However, by introducing a dominant negative FADD mutant that blocks 
death receptor signaling we provided evidence that increased death sensitivity in 
p16INK4A expressing T-ALL cells can be ascribed to distinct changes in the composition of 
pro- and anti-apoptotic BCL2-proteins at the level of mitochondria (Obexer et al, 2009a). 
Whereas the potent pro-apoptotic protein BBC3/Puma accumulated in p16INK4A 
expressing CCRF-CEM and Molt4 cells, the pro-survival proteins BCL2 and MCL1 were 
downregulated after 24 hours and completely lost after 48 hours of p16INK4A expression. 
Although p16INK4A-expressing T-ALL cells did not undergo programmed cell death 
spontaneously within 48 hours, these significant changes in the balance of pro- and 
antiapoptotic BCL2-proteins reduce the capacity of T-ALL cells to cope with additional 
apoptotic signals such as binding of death-ligands or glucocorticoid-induced cell death 
(Figure 3). We demonstrated the relevance of Puma, BCL2 and MCL1 by retroviral 
overexpression and knock down, but did not further investigate other forms of cell death 
(Obexer et al, 2009a). Concerning the observation that p16INK4A expression renders T-ALL 
cells less sensitive to bortezomib, we found that p16INK4A reconstitution induced rapid 
loss of the BH3-only protein PMAIP1/Noxa in both CCRF-CEM T-ALL and Molt4 T-ALL 
cells (Obexer et al, 2009a). Noxa is a “weak” BH3-only protein that does not neutralize all 
pro-survival BCL2-proteins, but preferentially binds to MCL1, BCL2A1/A1 (Willis et al, 
2007) and, as recently shown by our group also to BCL2L1/Bcl-xL. Noxa acts as a sensitizer 
that critically regulates the sensitivity to e.g. proteasome-inhibition-induced cell death 
(Hagenbuchner et al, 2010). The rapid loss of Noxa upon p16INK4A reconstitution might 
therefore explain, why p16INK4A-expressing T-ALL cells show reduced sensitivity to 









Fig. 4. p16INK4A expression differentially affects the sensitivity of T-ALL cells to various 
death-inducing agents. T-ALL cells expressing p16INK4A in a tetracycline-regulated 
manner were cultured for 24 hours in the presence of doxycycline (200 ng/ml) to switch on 
p16INK4A expression and were then treated with the therapeutic agents doxorubicin (8 
µM), etoposide (8 µM), vincristine (8 µM), dexamethasone (10 nM) and bortezomib (10 nM) 
for  additional 24 hours. To activate death receptor signaling an anti-Fas-receptor antibody 
(clone CH11, 0.1 µg/ml) was applied for 4 hours. Cells were resuspended in hypotonic 
propidium-iodide containing buffer according Nicoletti et al (Nicoletti et al, 1991) and the 
percentage of apoptotic cells was assessed in a Beckman-Coulter FC500 flow cytometer. 
Shown is the mean of three independent experiments.  
However, additional levels of apoptosis modulation by p16INK4A in T-ALL cells exist. One  
protein that is highly expressed in many cancers e.g. in up to 65% of acute lymphoblastic B-
cell leukemia is the anti-apoptotic protein BIRC5/Survivin (Troeger et al, 2007). Survivin 
belongs to the family of Inhibitor of Apoptosis Proteins (IAPs) that are characterized by so 
called BIR domains that allow them to interact with caspases and other molecules involved 
in cell death signaling. Survivin has also additional functions since it acts as a chromosomal 
passenger protein and blocks apoptosis induction at the level of mitochondria (Obexer et al, 
2009b). Recently, it was shown that mice overexpressing Survivin in hematopoietic stem 
cells show a high incidence of hematologic tumors. This pro-oncogenic effect of Survivin 
was not due to increased proliferative potential but to increased death resistance of 
hematologic cells (Small et al, 2010).  
Interestingly, the loss of p16INK4A during leukemogenesis apparently contributes to high 
levels of Survivin in T-ALL cells: in leukemia cells engineered to express p16INK4A the 
Survivin steady state expression levels are completely repressed upon p16INK4A induction 
(Figure 5A). To directly assess the relevance of Survivin-repression for changes in apoptosis 
sensitivity we retrovirally transduced human Survivin into T-ALL cells with conditional 
p16INK4A expression. As shown in Figure 5A this ectopic Survivin compensates for the loss 
of the endogenous protein during p16INK4A expression. Interestingly, ectopic Survivin 
prevented FAS-induced death sensitization (Figure 5B), but did not affect the increased 
sensitivity of p16INK4A-expressing T-ALL cells to glucocorticoid-induced cell death (Figure 






induced apoptosis triggered by FAS-ligand. Therefore, the effects of p16INK4A in leukemia 
cells by far extend the generally described effect as an inhibitor of cell cycle progression.  
 
 
Fig. 5. High levels of p16INK4A in human CCRF-CEM T-ALL cells repress the IAP family 
member Survivin, which is critical for increased FAS-induced cell death, but not for 
p16INK4A-induced sensitization to glucocorticoid-induced apoptosis. A) CEM/Ctr cells 
stably express the reverse tet-transactivator rtTA, CEM/p16 cells are derivatives that 
contain the rtTA and express human p16INK4A under the control of a tetracycline 
responsive CMV promoter (Ausserlechner et al, 2001). In presence of 200 ng/ml 
doxycycline, p16INK4A expression is induced, which causes complete loss of Survivin 
within 48 hour. Retrovirally transduced Survivin compensates for the loss of the 
endogenous protein in CEM/p16-Survivin cells. Re-expression of p16INK4A accelerates 
death-receptor-induced (anti-FAS anibody, 0.1 mg/ml, for four hours) and glucocorticoid-
induced apoptosis (10 nM dexamethasone, 24 hours) as shown in B und C (Obexer et al, 
2009a). Ectopic expression of Survivin did not change the sensitivity to dexamethasone (C), 
but prevents increased sensitivity to Fas-induced apoptosis (B). The amount of apoptotic 
cells was assessed by flow cytometric analysis of propidium-iodide stained nuclei. Each bar 
represents the mean of three independent experiments.  
8. Conclusions 
The INK4A genes were discovered in the mid-90s of the last century and intensive studies 





 – Connecting Cell Cycle Control to Cell Death Regulation in Human Leukemia 
 
127 
cell cycle regulation (and de-regulation) in normal and malignant cells. Despite all this effort 
and progress, continuously new aspects of p16INK4A and ARF are discovered, which 
highlight their diverse functions beyond the inhibition of the cell division cycle. In this 
chapter we reviewed current findings on how these INK4A-encoded genes are regulated in 
hematopoietic stem cells and that these proteins also represent a barrier to the artificial 
generation of pluripotent stem cells from normal differentiated tissue. In addition, both 
proteins also contribute to death sensitivity: ARF by activating p53 via a well defined 
pathway, p16INK4A by directly or indirectly affecting the expression and activity of critical 
death regulators such as BCL2 proteins, death ligands or pro-survival proteins such as 
Survivin. Under normal, physiologic conditions these significant changes in death 
sensitivity may determine a deadly barrier for cells that try to return to a less differentiated 
state and also for precancerous cells that lose proliferative control. These novel findings 
implicate that INK4A proteins are not “only cell cycle brakes” but serve as gatekeepers that 
keep the doors closed for those cells that want some piece of “stemness”. 
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